You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Geron Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Geron Company Info
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
News & Analysis
The binary nature of biotech investing is making itself obvious from recent study results.
The company said it expects to submit a new drug application for its lead candidate early next year.
Investors are reacting positively to the company's Q1 update.
The late clinical-stage biopharmaceutical company is raising money through a stock offering.
It could be a while before Geron has a big catalyst.
Investors are cheering the company's encouraging phase 2 data.
The company released its latest quarterly update, and investors were not impressed.
The bio pharmaceutical announced fresh data on imetelstat that it will present at a key conference next month.
GERN earnings call for the period ending September 30, 2022.
GERN earnings call for the period ending June 30, 2022.
GERN earnings call for the period ending March 31, 2022.
GERN earnings call for the period ending December 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.